Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
Recruiting · Phase 1 · NCT06482268
Conditions: PD - Parkinson's Disease
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 7
About the trial
- Sponsor
- University of California, San Diego (with Sumitomo Pharma America, Inc., Kyoto University, Sumitomo Pharma Co., Ltd.)
- Tested
- Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001) (combination_product)
- Dates
- Started 2024-06-01; completion 2028-05
- Results posted
- Not yet
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
From ClinicalTrials.gov, last updated 2026-08-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma Co., Ltd. reported $1.3M in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Regents of the University of California San Diego $1.3M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.